[Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome].
The purpose of the study was to compare the effectiveness of normodipin and nebivolol for correction of platelet dysfunction in patients with metabolic syndrome. Normodipin was administered to 25 patients during three months in a dose of 10 mg a day. Nebivolol was administered to 21 patients in a dose of 5 mg a day. The dynamics of anthropometric indices, lipid blood spectrum, lipid peroxidation in the plasma and platelets, the antioxidant protection of the liquid part of blood and platelets, and aggregative platelet activity were evaluated. The results were processed using Student's criteria and system multi-factor analysis. The use of normodipin effected peroxidation syndrome more positively, and optimized platelet function to a greater extent that nebivolol. Long-term administration of normodipin is able to stabilize the achieved effect. To lower body weight in patients with arterial hypertension with metabolic syndrome normodipin application should be combined with non-drug treatment.